Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Oct 29, 2023 1:41pm
111 Views
Post# 35706371

RE:About the Pancreatic Cancer Action Network (PanCAN)

RE:About the Pancreatic Cancer Action Network (PanCAN)PanCAN’s SMAB includes leading scientists, clinicians and healthcare professionals who specialize in pancreatic cancer from institutions across the United States.

Current SMAB members Eileen M. O’Reilly, MD, from Memorial Sloan Kettering Cancer Center (MSK) and Gregory Beatty, MD, PhD, step into the roles of Chair and Vice Chair, respectively.


https://pancan.org/news/pancan-welcomes-new-leadership-and-new-members-to-pancans-scientific-medical-advisory-board/

Dr. O’Reilly’s researcincludes development of adjuvant and neoadjuvant therapies and identification of biomarkers for therapy selection.

https://www.esmo.org/about-esmo/biographies/eileen-m.-o-reilly

Dr. Beatty’s research reproduces inflammation within the tumor microenvironment (TME) as is seen in human cancers and has found that macrophages linked to cancer can be therapeutically targeted and converted from tumor-promoting to tumor-suppressing. 

https://gabriellesangels.org/bio/gregory-l-beatty-md-phd/
<< Previous
Bullboard Posts
Next >>